All posts by medical

Carolina Union event space reservations to be available starting in November – The Daily Tar Heel

Amisha Garikipati, a junior neuroscience major at UNC, is on the executive board of the Carolina Neuroscience Club. Garikipati said the club has faced difficulties in recruiting new members due to the pandemic.

While the club has been meeting virtually instead of at the Student Union, Garikipati said one positive of going online is that it has presented new opportunities for the club and a chance to attract more people through new platforms.

Even though we do have a fewer turnout now, it has presented some opportunities that wouldn't have been possible before," Garikipati said. "We had someone from the neuroscience club in South Carolina reach out to us and see if we could potentially collaborate."

Garikipati said she is not sure if the club would use the event reservation ability for the spring semester. If members thought it was safe and beneficial, she said the club would do it.

"But I guess we would have to see how things are doing at that point in time and reach out to our members and see if they are comfortable with that and if that's something they'd want to do," she said.

Megan Wagner, a sophomore economics and communications major, serves as secretary for the UNC Young Democrats. She said the club has had a significant decrease in new member recruits due to COVID-19.

"It's just a lot harder to work around getting people to come to meetings in general, especially since everything is virtual and classes have been moved back, so the timing of everything is a lot harder," Wagner said.

Prior to the pandemic, Wagner said UNC Young Democrats reserved a room to hold their weekly cabinet meetings and other events which in the past have included hosting Beto ORourke at the Student Union.

We've used it a lot to host voter registration and lit drops," Wagner said. "Its just a place for everyone to meet, get the materials that we need and disperse off to where you need to go."

Wagner said the club is not yet certain whether it will use the Union in the spring semester. But some precautions she would personally like to see are temperature screenings, hand sanitizer stations, masks required and 6 feet of social distancing.

It really depends on so many different things if we're on campus, if COVID is not as rampant as it is currently and we are able to safely have officer meetings, then probably," Wagner said. "But if it's not safe, then well probably just stick to virtual."

university@dailytarheel.com

Continued here:
Carolina Union event space reservations to be available starting in November - The Daily Tar Heel

Cogstate Expands Executive Team with Key Scientific Appointments – GlobeNewswire

Melbourne, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Neuroscience technology company, Cogstate Ltd (ASX.CGS), announced today the appointment of Chris Edgar, PhD as Chief Science Officer and Prof. Paul Maruff, PhD as Chief Innovation Officer. These appointments represent an expansion of the executive leadership team with strengthened scientific capacity as the company continues to meet the growing demand for transformative innovations in clinical trials and healthcare.

As Chief Science Officer, Dr. Edgar will continue to advise Cogstate customers on clinical endpoint strategy and will set the strategic vision for Cogstates global scientific services. He will lead a team of clinical experts focused on the optimization, execution and analyses of cognitive and behavioral assessments and related data quality assurance solutions for improved signal detection and excellence in trial design and conduct.

Moving into the newly created role of Chief Innovation Officer, Prof. Maruff will lead efforts to continue to refine existing Cogstate technologies as well as identifying and developing novel methods for assessment of cognition and behaviour. He will continue to oversee Cogstate relationships supporting innovation and development with partners from pharmaceutical and biotechnology companies and with key industry and academic groups central to the scientific advancements of Cogstate technologies.

Adding scientific strength to the Cogstate leadership team will further position us for this current phase of growth as we continue to see increasing demand for strong, stable delivery supported by rapid, robust innovation, said Brad OConnor, Cogstate CEO. Among the current opportunities for the company are awards in late phase global clinical trial programs, the increased need for remote data collection and smart-phone based assessment, as well as rapidly evolving needs in healthcare for early detection of cognitive impairment. Dr. Edgars experience in pharmaceutical and contract research organizations brings an enormous depth to our drug development expertise and measurement science excellence in clinical trials. With his expertise, Paul can re-double his efforts to bring forward new strategies for measuring disease-related and treatment-related changes in cognition, remaining at the center of innovation at Cogstate.

About Chris Edgar

Dr. Chris Edgar is an experienced leader in cognitive assessment and clinical endpoint strategy who provides expert guidance to Cogstates pharmaceutical customers throughout all stages of trial conduct, from study design and test selection through final analysis. Dr. Edgar is also a key advisor to Cogstates commercial and product teams for the application of new technologies and approaches aligned with industry needs. Prior to joining Cogstate as Senior Vice President, Clinical Science in 2018, Dr. Edgar oversaw clinical endpoint strategy for multiple neuroscience indications in the Patient-Centered Outcomes Research group at Roche. He holds a PhD in psychopharmacology from Northumbria University and has nearly two decades of pharmaceutical industry experience. Dr. Edgar has held other key industry positions including Clinical Scientist at Roche on Schizophrenia and Alzheimers disease drug development programs, Senior Clinical Lead for rater training and data quality at Bracket, and Scientific Director at Cognitive Drug Research Ltd., a computerized cognitive assessment company.

About Paul Maruff

Professor Paul Maruff is one of the founders of Cogstate and served as Chief Science Officer before taking on the role of Chief Innovation Officer. He is a neuropsychologist with expertise in the identification and measurement of subtle behavioral and cognitive dysfunction. Prof. Maruffs research integrates conventional and computerized neuropsychological testing with cognitive neuroscientific methods to guide decision making in drug development and in clinical medicine. He has worked extensively on methods to identify subtle neurocognitive impairmentand to assess the efficacy of pharmacological treatmentin Alzheimers disease, mild cognitive impairment and the HIV dementia complex. He has extended this approach to identify cognitive dysfunction and monitor treatment efficacy in psychiatric diseases such as schizophrenia, obsessive-compulsive disorder and depression in adults, attention deficit disorder, developmental dyspraxia and substance abuse in children. Paul remains an active researcher; he is appointed Professor at the Florey Institute for Neuroscience and Mental Health, and he is currently clinical co-chair of the Australian Imaging Biomarkers and Lifestyle (AIBL) study. Paul has published over 450 research articles in international peer-reviewed scientific journals and has co-authored 15 book chapters.

About Cogstate

Cogstate Ltd (ASX:CGS) is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerized cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The companys clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, in August 2019 Cogstate entered into an exclusive licensing agreement with pharmaceutical company Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. The product, branded as NouKNOW, launched in Japan on 31 March 2020 (nouknow.jp). To learn more, visit:http://www.cogstate.com/.

Read this article:
Cogstate Expands Executive Team with Key Scientific Appointments - GlobeNewswire

AMD EPYC Processors Deployed with Over 2 Petaflops of Computing Power – I-Connect007

AMD and Okinawa Institute of Science and Technology Graduate University (OIST) , announced the deployment of AMD EPYC 7702 processors for use in a new, high performance computing system. The EPYC processor-based supercomputer will deliver the 2.36 petaflops of computing power OIST plans to use for scientific research at the University.

The Scientific Computing & Data Analysis Section (SCDA) of OIST plans to implement the new supercomputer for supporting OIST computationally intensive research ranging from bioinformatics, computational neuroscience, and physics. SCDA adopted AMD EPYC after significant growth, including a 2X increase in users.

2020 is a milestone year for OIST with new research units expanding the number of research areas. This growth is driving a significant increase in our computational needs, said Eddy Taillefer, Ph.D., Section Leader, Scientific Computing & Data Analysis Section. Under the common resource model for which the computing system is shared by all OIST users we needed a significant increase in core-count capacity to both absorb these demands and cope with the significant growth of OIST. The latest AMD EPYC processor was the only technology that could match this core-count need in a cost-performance effective way.

Key factors of OISTs selection of the AMD EPYC processors included superior cost-performance, memory/PCIe bandwidth, and high core counts per server. OIST plans to also consider EPYC processors for other growing computational needs for University researchers in the future.

AMD is proud to be working with leading global institutions to bring scientific research to the forefront through the power of high performance computing technology, said Ram Peddibhotla, corporate vice president, EPYC product management, AMD. With high performance capabilities, ease of management and scalability, 2ndGen AMD EPYC processors can assist OIST researchers with advancing technological innovations and supporting their research goals in bioinformatics, computational neuroscience, and physics.

Excerpt from:
AMD EPYC Processors Deployed with Over 2 Petaflops of Computing Power - I-Connect007

Okinawa Institute of Science and Technology Graduate University Deploys AMD EPYC Processors with Over 2 Petaflops of Computing Power Dedicated to…

AMD EPYC Processors provide superior cost-performance and high core density

TOKYO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Today, AMD (NASDAQ: AMD) and Okinawa Institute of Science and Technology Graduate University (OIST) , announced the deployment of AMD EPYC 7702 processors for use in a new, high performance computing system. The EPYC processor-based supercomputer will deliver the 2.36 petaflops of computing power OIST plans to use for scientific research at the University.

The Scientific Computing & Data Analysis Section (SCDA) of OIST plans to implement the new supercomputer for supporting OIST computationally intensive research ranging from bioinformatics, computational neuroscience, and physics. SCDA adopted AMD EPYC after significant growth, including a 2X increase in users.

2020 is a milestone year for OIST with new research units expanding the number of research areas. This growth is driving a significant increase in our computational needs, said Eddy Taillefer, Ph.D., Section Leader, Scientific Computing & Data Analysis Section. Under the common resource model for which the computing system is shared by all OIST users we needed a significant increase in core-count capacity to both absorb these demands and cope with the significant growth of OIST. The latest AMD EPYC processor was the only technology that could match this core-count need in a cost-performance effective way.

Key factors of OISTs selection of the AMD EPYC processors included superior cost-performance, memory/PCIe bandwidth, and high core counts per server. OIST plans to also consider EPYC processors for other growing computational needs for University researchers in the future.

AMD is proud to be working with leading global institutions to bring scientific research to the forefront through the power of high performance computing technology, said Ram Peddibhotla, corporate vice president, EPYC product management, AMD. With high performance capabilities, ease of management and scalability, 2nd Gen AMD EPYC processors can assist OIST researchers with advancing technological innovations and supporting their research goals in bioinformatics, computational neuroscience, and physics.

AMD EPYC 7702 Processor Specifications

Supporting Resources

About AMDFor 50 years AMD has driven innovation in high-performance computing, graphics, and visualization technologies the building blocks for gaming, immersive platforms, and the datacenter. Hundreds of millions of consumers, leading Fortune 500 businesses and cutting-edge scientific research facilities around the world rely on AMD technology daily to improve how they live, work and play. AMD employees around the world are focused on building great products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) website, blog, Facebook and Twitter pages.

1 Max boost for AMD EPYC processors is the maximum frequency achievable by any single core on the processor under normal operating conditions for server systems. EPYC-18

AMD, the AMD Arrow logo, EPYC, and combinations thereof, are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners.

Contact:Gary SilcottAMD Communications(512) 602-0889gary.silcott@amd.com

Laura GravesAMD Investor Relations(408) 749-5467laura.graves@amd.com

Read the original here:
Okinawa Institute of Science and Technology Graduate University Deploys AMD EPYC Processors with Over 2 Petaflops of Computing Power Dedicated to...

Former Ghoraghat UNO Wahida Khanam, who was critically injured in an attack, comes out of the National Institute of Neuroscience and Hospital (NINH)…

Vendor Information

Editor: A.M. MUFAZZAL, Managing Editor: ARSHAD HOSEIN. Printed and published by MAINUL HOSEIN from the New Nation Printing Press. The New Nation, 1 R.K. Mission Road,Ittefaq Bhaban (3rdfloor), Dhaka-1203, Bangladesh,Phones: PABX: 47115875, 47115879, 47114514,Fax : 880-2-47115865, Email: For News: n_editor@bangla.net, n_news@bangla.net,For Advertisement nnation@bangla.net

View post:
Former Ghoraghat UNO Wahida Khanam, who was critically injured in an attack, comes out of the National Institute of Neuroscience and Hospital (NINH)...

New programme explores the vital role of education and awareness in prevention and management of allergies, anaphylaxis and rare diseases -…

The British Society of Allergy and Clinical Immunology (BSACI) and ITN Productions Industry News have co-produced a news-style programme raising awareness and education around allergies, anaphylaxis, clinical immunology and rare diseases to help improve health outcomes and prevent the tragic loss of life.For those living with life threatening food allergies, compromised respiratory functions or immune systems, the misinformation surrounding allergies and the current pandemic crisis is especially concerning. The risk of anaphylaxis due to severe allergies means for many, returning to a new normal after lockdown will be a particularly anxious time. Anchored by ITN Productions Industry News presenter Samantha Simmonds, Allergy and Clinical Immunology Attention Needed! explores the latest advancements in prevention and management of allergies, in particular food allergies, anaphylaxis and rare diseases often mistaken for an allergy. The programme hears from families who have lost loved ones to anaphylaxis and how the devastating deaths could have been avoided. Passionate about bringing change to prevent further loss of life, BSACI highlights the importance of greater awareness, education and training in schools and society, clearer messaging and information across food packaging and restaurant menus and the importance of checking dates on life-saving medication as some of the fundamental factors critical to improving outcomes.Launching at the British Society for Allergy and Clinical Immunology's Annual Digital Conference on 2 October 2020, the programme will form part of an extensive awareness campaign. Professor Adam Fox, President of BSACI said: Sadly people are dying in the UK as a result of their allergies, these deaths could have been prevented had appropriate safeguards been put in place. Our aim is to raise awareness of allergies and the impact these have on the everyday lives by working with patients and decision makers to bring about change.Elizabeth Fisher-Robins, Head of ITN Productions Industry News said: Were delighted to be partnering with the British Society of Allergy and Clinical Immunology to produce a programme to help raise awareness of the need for greater education and awareness of allergies and anaphylaxis. The current pandemic has caused increasing challenges for those living with allergies and we hope the films will provide a platform to stimulate discussion and advance solutions and policy.The programme features key interviews and reports with sponsored editorial profiles from the following leading companies:

Mylan NovartisTakedaMast Cell Action

Allergy and Clinical Immunology Attention Needed! can be viewed directly here via the BSACI website

For further information please contact Fiona Rayner at BSACI 0207 501 3910 or email info@bsaci.org

-Ends-About ITN Productions Industry NewsITN Productions produces bespoke creative and commercial content for broadcasters, businesses, brands, rights holders and digital channels. Industry News forms part of this offering and is a communications tool for leading industry bodies and national associations produced in a broadcast news-style programme format, including interviews, news items and sponsored editorial profiles. For more information visit: ITN Productions

About the British Society of Allergy and Clinical ImmunologyThe BSACI began life as a small interest group for allergists but has grown to become a major force in medicine in the UK with over 900 members working across many medical specialities including allergy, immunology and paediatrics, ENT, dermatology, respiratory medicine and primary care.The BSACI is the national, professional and academic society which represents the specialty of allergy at all levels. Its aim is to improve the management of allergies and related diseases of the immune system in the United Kingdom, through education, training and research. One of the BSACI's main activities is the formulation of National Guidelines for use by allergy specialists. The process used by the BSACI to develop these guidelines has been accredited by NICE. For more information visit: BSACI website

See the original post here:
New programme explores the vital role of education and awareness in prevention and management of allergies, anaphylaxis and rare diseases -...

Akiko Iwasaki and Gregg Gonsalves named among 50 experts to trust in a pandemic – Yale Daily News

Yale Medicine

Yale Professor of Immunology Akiko Iwasaki and Assistant Professor of Epidemiology Gregg Gonsalves 11 GRD 17 were named on the 50 experts to trust in a pandemic list. The list, curated by editors of the health and wellness publication Elemental, presents 50 professionals that people should follow on social media for evidence-based guidance during the pandemic.

According to the website for Elemental, the list promotes trustworthy sources to help the general public avert the pitfalls of misinformation while staying up-to-date with COVID-19 developments. Among the experts included are Director-General of the World Health Organization Tedros Adhanom Ghebreyesus, founder and director of Scripps Research Translational Institute Eric Topol and former director of the Centers for Disease Control and Prevention Tom Frieden.

Jeremy Faust, an emergency physician at Brigham and Womens Hospital and instructor at Harvard Medical School, was also featured in the list. Faust recently founded Brief 19 a project that provides readers with a daily recap of new information pertaining to the pandemic. He told the News that because so much about the pandemic is being politicized, physicians, scientists and public health experts should serve as a nonpartisan voice of reason for people to use as resources.

Our job as public health and research experts is to contextualize news in a way thats accurate and that doesnt increase hype and panic without the need to do so, Faust said. But also on the flipside, not to downplay when things are serious.

According to Faust, following experts on social media gives people access to balanced views and important context that mainstream outlets usually do not discuss, such as the research methods behind the discoveries that make the headlines, in addition to their reliability.

In an email to the News, Iwasaki wrote that she was delighted to be part of the list. She also added that she feels a strong sense of duty as a scientist to provide a knowledgeable perspective surrounding what has been discovered and what remains unknown about COVID-19. Iwasaki told the News that access to experts opinions allows people to make more informed decisions, making it fundamental for scientists to communicate their thoughts to a wider audience.

There is a lot of sensational media coverage out there that is either misinformation or mis-guided information, Iwasaki wrote. I want to provide a voice from my scientific expertise in immunology.

Iwasakis lab at the Yale School of Medicine explores how immunity is initiated and sustained. As someone who is at the forefront of COVID-19 research, she has been featured in news outlets across the globe and is an active voice within the scientific realm of Twitter. In addition to being a professor at Yale, Iwasaki is also a principal investigator at the Howard Hughes Medical Institute.

In her case, Iwasaki said that she relies on experts in fields such as epidemiology, modeling and health policy to illuminate what the media is reporting on with a professional viewpoint.

With so many opinions flying around the internet, it is important for me to hear what the experts have to say on important issues for COVID-19 transmission and control, Iwasaki wrote.

Although Gonsalves did not respond to requests for comments from the News, he tweeted that he was honored even to be named in the same sentence as Dr. Iwasaki. He also added that he took Iwasakis immunobiology course when he was an undergraduate student at Yale, and that, as a colleague, she is a role model for [him] and many on how to be an ethical, caring scientist and academic.

Gonsalves was an HIV/AIDS activist for over 30 years and currently works with infectious disease epidemiology. In addition to being a professor at the Yale School of Public Health, he is also an associate professor of Law at the Yale Law School.

Hanna Ehrlich GRD 22, a doctoral student at the School of Public Health and a fellow at the Global Health Justice Partnership, wrote in an email to the News that those who are unfamiliar with epidemiology can often dismiss the importance of history in the translation and practice of science in society. However, she wrote, Gonsalves has been through this before, fighting for accessible science in the face of myriad political obstacles during the AIDS epidemic in the 1990s.

On campus, Gonsalves spearheads initiatives including the Global Health Justice Partnership which focuses on the cross section between global health, human rights and social justice and the Collaboration for Research Integrity and Transparency which aims to improve the quality and transparency of evidence behind medical products. On Twitter, Gonsalves has also been active in debunking misinformation and exposing those who distort scientific and public health guidance for political or ulterior motives.

Gregg calls out B.S. like no one else, Ehrlich wrote. But he also acknowledges the limitations and strengths of scientific evidence, giving his audience more agency than others might.

According to Elizabeth White GRD 22, who is also a doctoral student at the School of Public Health and fellow at the GHJP, Gonsalvess career both in HIV/AIDS activism and as a professor has largely centered on how political systems can engender structural inequities and health disparities.

In Gonsalves course Political Epidemiology, White says that he teaches students how to methodically analyze the impact of policy decisions on population health outcomes, especially for infectious diseases such as HIV. To White, his course shapes students into educated consumers of studies.

White also wrote that one of Gonsalves greatest strengths as teacher, public health leader and Twitter communicator is that he tells it like it is, based on data and his wealth of experiences.

Iwasaki told the News that while professional perspectives are important, it can be dangerous for people to speak with authority on areas that do not fall within their own field of expertise. Iwasaki said that she knows for herself the boundaries of [her] expertise and knowledge and will only speak of what [she is] capable of evaluating.

Iwasaki also commented on a lack of diverse representation in the media when it comes to spotlighting scientific experts.

Women and people of color are not being well represented as experts speaking on social and traditional media, Iwasaki wrote. This unfortunately turns the clock backwards on any progress we were making before the pandemic for what a scientist looks like. For this reason, I feel even more committed to speaking to the media and through social media to disseminate scientific truth.

Iwasaki did tell the News, however, that she believes that the 50 experts list did a great job in representing a diverse group of scientists.

Hannah Ro 22 told the News that she started following Iwasaki on Twitter during the pandemic and enjoys keeping up with the research she shares. To Ro, who is enthusiastic about science and public health, Iwasaki is a role model.

When I see Dr. Iwasaki on Twitter and on the news Im really inspired, Ro said, First of all because shes a woman and second of all because shes Asian, and for me to see an Asian woman being a leader in her field is just really cool.

As of Oct. 1, there have been 7.3 million diagnosed cases of COVID-19 in the United States.

Maria Fernanda Pacheco | maria.pacheco@yale.edu

Link:
Akiko Iwasaki and Gregg Gonsalves named among 50 experts to trust in a pandemic - Yale Daily News

Government COVID-19 testing lab to open at the University of Birmingham – University of Birmingham

The addition of the lab will make Birmingham the first university campus in the UK with end to end pillar two testing capabilities.

As part of the drive to expand COVID-19 testing capacity across the UK, The University of Birmingham has been announced today as one of the first academic sector lab partnerships to come online. The lab, based at the University of Birminghams Medical School, will form part of NHS Test and Trace, joining Britains largest network of diagnostic testing facilities increasing coronavirus testing capacity.

The new facilities will help to increase sample processing capacity, with the number of tests that can be processed gradually increasing over the coming months. The Birmingham lab will be the first of the new facilities to open, delivering over 3,000 tests per day over the coming months.

Set up by a multi-disciplinary team from the Institutes of Immunology and Immunotherapy and Microbiology and Infection, the lab will be headed up by infectious disease expert Professor Alan McNally, who will manage a team of over 40 lab staff, many of whom have been recruited to support the facility. Professor McNally has already played a significant role in the fight against COVID-19 having been seconded into the role of Infectious Disease Lead at the governments first flagship Lighthouse Lab in Milton Keynes.

Professor McNally said: Im thrilled to be involved with this next phase of the governments national testing programme. What has been achieved in establishing this lab in such a short space of time is testament to the dedication of the team at the University who have worked tirelessly to ensure we are in a position to begin processing samples as soon as next week.

Professor Alex Richter from the Universitys Institute of Immunology and Immunotherapy, who has played an integral role in setting up the lab from logistics to the recruitment and training of lab staff, said: This has been a huge team effort, drawing on all our resources, retraining staff from the University of Birminghams Clinical Immunology Service, Estates, Finance, Human resources and IT departments and collaborating with University Hospitals Birmingham virologists.

Professor David Adams, Head of the College of Medical and Dental Sciences said: From ground breaking research to the selflessness of our staff and students who mobilised to support our local community and the NHS, the University has made important contributions to both the national and the global COVID effort. The opening of this new lab is only possible because we havespecialist facilitiesand particularly highly skilled anddedicated staff who want to contribute to thewider national response to COVID-19.

The lab will work in parallel to the recently launched on-campus community testing site located at the Southgate entrance, which opened in early September. The testing site is open to staff, students and the local communityand offers testing for anyone with coronavirus symptoms. The addition of the lab will make Birmingham the first university campus in the UK with end to end pillar two testing capabilities.

For more information please contact Sophie Belcher, Communications Manager, University of Birmingham, on +44 7815607157. Alternatively, contact the Press Office out of hours on +44 (0)7789 921165.

Filming/photography requests or requests for interview should be directed to pressofficenewsdesk@dhsc.gov.uk

About the University of Birmingham

The University of Birmingham is ranked amongst the worlds top 100 institutions, and its work brings people from across the world to Birmingham, including researchers and teachers and more than 6,500 international students from nearly 150 countries.

More here:
Government COVID-19 testing lab to open at the University of Birmingham - University of Birmingham

Sonoma Biotherapeutics Expands Series A Financing to $70 Million and Appoints Key Executives to Advance Regulatory T-cell Therapies in Autoimmune and…

SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)--Sonoma Biotherapeutics, a privately held company developing regulatory T-cell (Treg) therapies for autoimmune and degenerative diseases, announced that it has raised an additional $30 million from investors in its Series A financing, bringing the total to $70 million. Investors participating in the round include Lyell Immunopharma, ARCH Venture Partners, 8VC, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Alexandria Venture Investments, the JDRF T1D Fund and additional undisclosed investors.

Sonoma also announced three new appointments to the senior management team: Leonard Dragone, M.D., Ph.D., joins as chief medical officer; Sejal Hall, Ph.D., joins as vice president of portfolio, program and alliance management; and Susan Lacy, Ph.D., joins as vice president of discovery. They join an experienced team steeped in next-generation research, development and manufacturing capabilities in immunology, cell therapy and genetic engineering.

We have made significant progress in a short amount of time in our mission to move adoptive cell therapy beyond cancer and into other disease areas, including autoimmunity and neuroinflammation, said Co-Founder and CEO Jeffrey Bluestone, Ph.D. Our progress in applying cell therapy to reprogram the immune system to alter the course of disease has attracted the attention and the vision of talented scientists and drug developers, as well as proven investors.

This expansion of the Sonoma team and the Series A financing will enable Jeff and the rest of the organization to continue their great progress, said Dr. Rick Klausner, executive chairman of Lyell Immunopharma and chair of the Sonoma Biotherapeutics board of directors. They are well poised to drive the next generation of cell therapy forward to advance treatments and potentially cures for patients with significant unmet medical need.

About Treg Cell Therapy

The goal of Treg therapy is to restore a state of self-tolerance by halting harmful inflammatory responses in autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis, along with degenerative diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimers. Over 50 million Americans currently live with an autoimmune disease, and millions more with some form of degenerative disease. For many, existing therapies are ineffective at controlling their disease.

Treg cells have a clear role in many of these conditions. These cells natural ability to migrate to inflamed tissues and control harmful immune responses makes them ideal for treating a range of conditions. In addition, the ability to engineer Treg cells to target specific disease-causing antigens reduces the potential for unwanted systemic effects. The role of Treg cells in tissue maintenance and repair offers the potential for effective, durable and restorative treatments.

About Sonoma Biotherapeutics

Sonoma Biotherapeutics is a South San Francisco and Seattle-based company leading the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies. More information at http://www.sonomabio.com.

See the original post:
Sonoma Biotherapeutics Expands Series A Financing to $70 Million and Appoints Key Executives to Advance Regulatory T-cell Therapies in Autoimmune and...

Beyond Air to Present Data on Nitric Oxide in the Treatment of Solid Tumors at the American Association for Cancer Research (AACR) Conference on Tumor…

GARDEN CITY, N.Y., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors and tumor metastases, today announced that a virtual poster presentation has been accepted for the AACR Conference on Tumor Immunology and Immunotherapy, which is being held from October 19th to 20th.

Virtual Poster Video Presentation at the AACR Tumor Immunology and Immunotherapy Conference:

About Beyond Air, Inc.Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. The LungFit can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit http://www.beyondair.net.

About Nitric Oxide (NO)Nitric Oxide (NO) is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens, including mycobacteria, viruses, fungi, yeast and parasites, and has the potential to eliminate multi-drug resistant strains.

About Solid Tumors Cancer is the second leading cause of death globally, with tumor metastases responsible for approximately 90% of all cancer-related deaths. Current cancer treatment modalities generally include chemotherapy, immunotherapy, radiation, and/or surgery. Nitric oxide at high concentrations has been reported to show anticancer properties and to serve as a chemosensitizer and radiotherapy enhancer. Based on its current findings, Beyond Air is developing treatment protocols using ultra-high nitric oxide concentrations to ablate primary tumors and treat metastatic disease.

Forward Looking StatementsThis press release contains forward-looking statements concerning inhaled nitric-oxide and the Companys LungFit product, including statements with regard to potential regulatory developments, the potential impact on patients and anticipated benefits associated with its use. Forward-looking statements include statements about our expectations, beliefs, or intentions regarding our product offerings, business, financial condition, results of operations, strategies or prospects. You can identify such forward-looking statements by the words anticipates, expects, intends, impacts, plans, projects, believes, estimates, likely, goal, assumes, targets and similar expressions and/or the use of future tense or conditional constructions (such as will, may, could, should and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to: our approach to discover and develop novel devices and drugs, which is unproven and may never lead to marketable products; our ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by our products; our ability to enforce our patents against infringers and to defend our patent portfolio against challenges from third parties; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of our product candidates, all of which are in various stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; our dependence on collaborators; our short operating history and other risks identified and described in more detail in the Risk Factors section of the Companys most recent Annual Report on Form 10-K and other filings with the SEC, all of which are available on our website. We undertake no obligation to update, and we do not have a policy of updating or revising, these forward-looking statements, except as required by applicable law.

CONTACTS:Steven Lisi, Chief Executive Officer Beyond Air, Inc.Slisi@beyondair.net

Corey Davis, Ph.D.LifeSci Advisors, LLCcdavis@lifesciadvisors.com (212) 915-2577

Read more:
Beyond Air to Present Data on Nitric Oxide in the Treatment of Solid Tumors at the American Association for Cancer Research (AACR) Conference on Tumor...